Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial

Authors:	Robert Dufour G. Kees Hovingh John R. Guyton Gisle Langslet Marie T. Baccara-Dinet Chantal Din-Bell Garen Manvelian Michel Farnier

Affiliation:	1. Institut de Recherches Cliniques de Montréal and Université de Montréal, Montréal, Quebec, Canada;2. Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands;3. Duke University Medical Center, Durham, NC, USA;4. Lipid Clinic, Oslo University Hospital, Oslo, Norway;5. Clinical Development, R&D, Sanofi, Montpellier, France;6. Biostatistics and Programming, Sanofi, Chilly-Mazarin, France;7. Regeneron Pharmaceuticals, Tarrytown, NY, USA;8. Lipid Clinic, Point Médical and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France

Abstract:
Keywords:	Alirocumab Familial hypercholesterolemia LDL-C Open-label extension PCSK9
本文献已被 ScienceDirect 等数据库收录！